Frazier Life Sciences has closed Frazier Life Sciences XI (FLS XI), exceeding its target of USD800 million and raising more than USD987 million in capital commitments in an oversubscribed fundraise.
FLS XI is Frazier Life Sciences’ fourth venture fund focused on biopharmaceuticals and represents a continuation of the team’s investment strategy of advancing innovative therapeutics through company creation, early-stage venture (Series A and Series B), and crossover and public investing.
FLS XI will be led by Managing Partners Patrick Heron and James Topper and General Partner Dan Estes, who have been with Frazier for 24, 20, and 12 years respectively. They lead an experienced team comprised of over 40 professionals who have a collective 700 years of experience in founding, operating, and investing in companies developing biopharmaceuticals.
Read more: Private Equity Wire
